Sandeep Dutta

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi request reprint Influence of cardiac output on dexmedetomidine pharmacokinetics
    S Dutta
    Clinical Pharmacokinetics and Toxicokinetics Department, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Pharm Sci 89:519-27. 2000
  2. ncbi request reprint Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers
    Sandeep Dutta
    Abbott Laboratories, 100 Abbott Park Road, Dept R4PK, Bldg AP13A, Abbott Park, IL 60064 6104, USA
    Epilepsy Res 49:1-10. 2002
  3. ncbi request reprint Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations
    Ronald C Reed
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Epilepsy Behav 8:391-6. 2006
  4. doi request reprint Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain
    S Dutta
    Department of Clinical Pharmacokinetics and Pharmacodynamics, Abbott, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 37:475-80. 2012
  5. pmc Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain
    Sandeep Dutta
    Clinical Pharmacokinetics and Pharmacodynamics, Abbott, Dept R4PK, Bldg AP13A, 100 Abbott Park Road, Abbott Park, Illinois 60064 6104, USA
    AAPS J 14:168-75. 2012
  6. ncbi request reprint Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium
    Ronald C Reed
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Am J Health Syst Pharm 61:2284-9. 2004
  7. ncbi request reprint Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC)
    Sandeep Dutta
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Pharm Sci 94:1949-56. 2005
  8. ncbi request reprint Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications
    Sandeep Dutta
    Clinical Pharmacokinetics, Abbott Laboratories, Abbott Park, IL 60064, USA
    Ann Pharmacother 40:619-25. 2006
  9. ncbi request reprint A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets
    Sandeep Dutta
    Abbott Laboratories, Dept R4PK, Bldg AP13A, 100 Abbott Park Road, Abbott Park IL 60064 6104, USA
    J Clin Pharmacol 46:952-7. 2006
  10. ncbi request reprint Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician
    S Dutta
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 31:321-9. 2006

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Influence of cardiac output on dexmedetomidine pharmacokinetics
    S Dutta
    Clinical Pharmacokinetics and Toxicokinetics Department, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Pharm Sci 89:519-27. 2000
    ....
  2. ncbi request reprint Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers
    Sandeep Dutta
    Abbott Laboratories, 100 Abbott Park Road, Dept R4PK, Bldg AP13A, Abbott Park, IL 60064 6104, USA
    Epilepsy Res 49:1-10. 2002
    ..Therefore, increasing the once-daily ER dose 14-20% while converting from a total daily DR dose given twice-daily results in equivalent exposure with lower C(max) and higher C(min) values...
  3. ncbi request reprint Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations
    Ronald C Reed
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Epilepsy Behav 8:391-6. 2006
    ..02). The DFL in VPA concentration with divalproex-ER can be minimized with once-daily administration and more so with q12h administration, compared with conventional enteric-coated divalproex taken q6h...
  4. doi request reprint Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain
    S Dutta
    Department of Clinical Pharmacokinetics and Pharmacodynamics, Abbott, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 37:475-80. 2012
    ..ABT-594 is a non-opioid, non-NSAID analgesic. The objective of this work was to characterize the population pharmacokinetics of ABT-594 in subjects with neuropathic pain...
  5. pmc Population analyses of efficacy and safety of ABT-594 in subjects with diabetic peripheral neuropathic pain
    Sandeep Dutta
    Clinical Pharmacokinetics and Pharmacodynamics, Abbott, Dept R4PK, Bldg AP13A, 100 Abbott Park Road, Abbott Park, Illinois 60064 6104, USA
    AAPS J 14:168-75. 2012
    ..Population pharmacodynamic models developed to characterize the improvement in pain score and incidence of adverse events indicate an approximately twofold separation between the ED(50) values for efficacy and AEs...
  6. ncbi request reprint Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium
    Ronald C Reed
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Am J Health Syst Pharm 61:2284-9. 2004
    ....
  7. ncbi request reprint Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC)
    Sandeep Dutta
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Pharm Sci 94:1949-56. 2005
    ..In conclusion, a Level A IVIVC describing the entire time-course of plasma concentrations was developed and validated, both internally and externally, for ER formulations of divalproex sodium...
  8. ncbi request reprint Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications
    Sandeep Dutta
    Clinical Pharmacokinetics, Abbott Laboratories, Abbott Park, IL 60064, USA
    Ann Pharmacother 40:619-25. 2006
    ..The distinct absorption characteristics of the conventional enteric-coated, delayed-release (DR) and the novel extended-release (ER) divalproex sodium formulations are not well recognized...
  9. ncbi request reprint A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets
    Sandeep Dutta
    Abbott Laboratories, Dept R4PK, Bldg AP13A, 100 Abbott Park Road, Abbott Park IL 60064 6104, USA
    J Clin Pharmacol 46:952-7. 2006
  10. ncbi request reprint Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician
    S Dutta
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 31:321-9. 2006
    ..We evaluated the effect of missing one or two doses of divalproex for up to 24 h, followed by replacement and resumption of scheduled therapy, on plasma valproic acid (VPA) concentrations...
  11. ncbi request reprint Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, IL 60064, USA
    Epilepsy Res 73:275-83. 2007
    ..Only divalproex-ER demonstrated true sustained-release characteristics...
  12. ncbi request reprint Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, Illinois 60064 6104, USA
    Clin Drug Investig 26:681-90. 2006
    ..In this study, the value of t((1/2)F) was calculated to characterise divalproex-ER steady-state concentration-time profiles...
  13. ncbi request reprint Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy
    S Dutta
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 32:365-71. 2007
    ..To characterize protein binding in patients with epilepsy who achieve transient high (>150 mg/L) total plasma concentrations following rapid valproate infusion at very high doses...
  14. ncbi request reprint Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration
    Sandeep Dutta
    Clinical Pharmacokinetics Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Am J Health Syst Pharm 61:2280-3. 2004
    ..The pharmacokinetics and safety of 1000-mg extended-release divalproex sodium given once daily either in the morning or evening were compared...
  15. ncbi request reprint Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Biopharm Drug Dispos 25:345-52. 2004
    ....
  16. ncbi request reprint Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Biopharm Drug Dispos 25:353-7. 2004
    ..80-1.25 interval...
  17. ncbi request reprint Effect of dexmedetomidine on propofol requirements in healthy subjects
    S Dutta
    Clinical Pharmacokinetics Department, Abbott Laboratories, 100 Abbott Park Road, Department 4PK, AP13A 3, Abbott Park, Illinois 60064 6104, USA
    J Pharm Sci 90:172-81. 2001
    ..Therefore, the propofol dose required for sedation and induction of anesthesia may have to be reduced in the presence of dexmedetomidine...
  18. ncbi request reprint Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects
    Sandeep Dutta
    Clinical Pharmacokinetics, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Pharm Pharmacol 54:641-7. 2002
    ..It was concluded that fiduxosin multiple-dose pharmacokinetics were dose-independent and time-invariant over the 30-120 mg/day dose range under fasting conditions...
  19. ncbi request reprint Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation
    Sandeep Dutta
    Abbott Laboratories, Department R4PK, Bldg AP13A 3, 100 Abbott Park Road, 60064 6104, Abbott Park, IL, USA
    Epilepsy Res 53:29-38. 2003
    ..v. loading dose in the uninduced population. A two-fold higher i.v. and oral maintenance regimen dose may be required in induced patients...
  20. ncbi request reprint Single- and multiple-dose pharmacokinetics of fiduxosin under nonfasting conditions in healthy male subjects
    Sandeep Dutta
    Clinical Pharmacokinetics, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharmacol 42:540-6. 2002
    ..Steady state was achieved after 4 days of qd dosing. Approximately 28% of the oral dose was eliminated by the fecal route as unchanged drug. Less than 1% of the unchanged drug was recovered in the urine after oral administration...
  21. ncbi request reprint Effect of food on the pharmacokinetics of fiduxosin in healthy male subjects
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    Eur J Drug Metab Pharmacokinet 27:49-52. 2002
    ..Tmax was not significantly different between fasting and nonfasting regimens. Food also decreased fiduxosin oral clearance (CL/F) by 60% and volume of distribution (Vbeta/F) by 75%...
  22. ncbi request reprint Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers
    Sandeep Dutta
    Abbott Laboratories, Department R4PK, Building AP13A, 100 Abbott Park Road, Abbott Park, IL 60064 6104, USA
    J Clin Pharmacol 44:737-42. 2004
    ..6 (24%) mg/h for a 500-mg tablet. Divalproex ER has a lower absolute bioavailability than conventional divalproex tablets but exhibits good extended-release characteristics without any dose dumping...
  23. doi request reprint Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy
    Ronald Charles Reed
    Global Pharmaceutical Research and Development Neuroscience, Abbott Laboratories, Abbott Park, IL 60064 6075, USA
    Epilepsy Res 87:260-7. 2009
    ..Divalproex-ER is the appropriate formulation for administration on a once-daily basis, especially if large total mg/day doses are required for the control of seizure activity...
  24. pmc Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials
    Ahmed A Othman
    Abbott Clinical Pharmacology and Pharmacometrics, Abbott Laboratories, Abbott Park, IL 60064, USA
    Br J Clin Pharmacol 75:1029-40. 2013
    ..To characterize quantitatively the relationship between ABT-102, a potent and selective TRPV1 antagonist, exposure and its effects on body temperature in humans using a population pharmacokinetic/pharmacodynamic modelling approach...
  25. ncbi request reprint Divalproex-ER pharmacokinetics in older children and adolescents
    Sandeep Dutta
    Abbott Laboratories, Abbott Park, Illinois, USA
    Pediatr Neurol 30:330-7. 2004
    ....
  26. ncbi request reprint Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Ronald C Reed
    Abbott Laboratories, Abbott Park, IL, USA
    Ther Drug Monit 28:413-8. 2006
    ..Despite the apparent smoothness of the VPA concentration-time profile after a once-daily divalproex-ER dose, the timing of the blood sample does matter and impacts the proper interpretation of the VPA concentration...
  27. doi request reprint Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers
    Ahmed A Othman
    Department of Clinical Pharmacokinetics and Pharmacodynamics, Abbott Laboratories, 100 Abbott Park Road, Bldg AP13A 3, Abbott Park, IL 60064, USA
    J Clin Pharmacol 51:512-26. 2011
    ..The pharmacokinetics, safety, and tolerability profiles of ABT-107 pose it as a good candidate for further development...
  28. pmc Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers
    Ahmed A Othman
    Abbott Clinical Pharmacology and Pharmacometrics, Abbott Laboratories, Abbott Park, IL 60064, USA
    Br J Clin Pharmacol 75:1299-311. 2013
    ....
  29. doi request reprint Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials
    Ahmed A Othman
    Abbott Laboratories, Abbott Park, IL, USA
    J Clin Pharmacol 52:1028-41. 2012
    ..4 (1.3-1.6) h(-1); solid-dispersion lag, 0.6 (0.5-0.8) h; solution lag, 0.3 (0.2-0.4) h; and solution F(rel), 40% (35%-45%). Evaluation of ABT-102 pharmacokinetic model indicated its robustness and adequacy...
  30. ncbi request reprint Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist
    E Samara
    Abbott Laboratories, Abbott Park, Illinois, USA
    J Clin Pharmacol 41:397-403. 2001
    ..The apparent volume of distribution was large (approximately 6 L/kg), consistent with extensive tissue distribution...
  31. doi request reprint What do the suffixes--XR, ER, Chrono, Chronosphere--really mean as it pertains to modified-release antiepileptic drugs?
    R C Reed
    Department of Neuroscience, Abbott Laboratories, Abbott Park, IL 60064 6075, USA
    J Clin Pharm Ther 35:373-83. 2010
    ..Such suffixes lack precise definition...
  32. ncbi request reprint Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy
    James C Cloyd
    College of Pharmacy, University of Minnesota, Minneapolis, MN, USA
    Epilepsy Res 53:19-27. 2003
    ..Measurement of unbound VPA may be useful when alterations in binding are suspected. Infusions up to 3mg/kg/min produce predictable total VPA concentrations when induction status and albumin levels are considered...
  33. ncbi request reprint Safety of rapid intravenous loading of valproate
    Nita A Limdi
    Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL 35294 0021, USA
    Epilepsia 48:478-83. 2007
    ..The present study was designed to evaluate the safety of administration of undiluted VPA (20 or 30 mg/kg/min) administered intravenously at rates of 6 or 10 mg/kg/min...
  34. ncbi request reprint Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium
    Sandeep Dutta
    Am J Health Syst Pharm 63:904-6. 2006
  35. ncbi request reprint Quantification of emphysema severity by histogram analysis of CT scans
    Paulo R S Mendonça
    GE Research Center, Niskayuna NY 12309, USA
    Med Image Comput Comput Assist Interv 8:738-44. 2005
    ..Experimental results with 81 cases of emphysema at different stages of disease progression show good agreement against the reading of an expert radiologist...
  36. ncbi request reprint A three-dimensional-weighted cone beam filtered backprojection (CB-FBP) algorithm for image reconstruction in volumetric CT-helical scanning
    Xiangyang Tang
    GE Healthcare Technologies, 3000 N Grandview Blvd, W 1190, Waukesha, WI 53188, USA
    Phys Med Biol 51:855-74. 2006
    ....